Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013

Int J Dermatol. 2017 Apr;56(4):405-414. doi: 10.1111/ijd.13434. Epub 2017 Jan 13.

Abstract

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare skin condition typically caused by medications. The objective of this study was to examine the clinical features, causes, and outcomes of AGEP at a sole tertiary care center.

Methods: A retrospective review of patients with AGEP (European Study of Severe Cutaneous Adverse Reactions score of ≥ 5) seen at Mayo Clinic (Rochester, MN, USA) between January 1, 1996, and December 31, 2013, was conducted.

Results: Of 28 patients (mean age at onset: 56 years), 17 (61%) were women. The development of AGEP was attributed to medications in 25 patients (89%), with clindamycin the most common culprit (six patients). Three patients (11%) had mucous membrane involvement, and 21 (75%) showed systemic involvement. Ten patients (36%) received systemic corticosteroids for treatment of AGEP. Skin findings resolved within 15 days in 26 patients (93%) (mean time to resolution: 7.6 days). In three patients (11%), generalized skin eruptions or dermatitis developed weeks to months after the resolution of AGEP. Twenty-four patients (86%) had a personal history of drug reactions before the development of AGEP.

Conclusions: A previous history of drug reactions and clindamycin causation were more common in the present cohort than in prior reports. A small subset of patients experienced new-onset non-AGEP skin eruptions within a few months of the resolution of AGEP.

MeSH terms

  • Acute Generalized Exanthematous Pustulosis / drug therapy*
  • Acute Generalized Exanthematous Pustulosis / etiology*
  • Acute Generalized Exanthematous Pustulosis / pathology
  • Administration, Cutaneous
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Clindamycin / adverse effects
  • Dermatitis / etiology
  • Drug Therapy, Combination
  • Female
  • Fluocinolone Acetonide / analogs & derivatives
  • Fluocinolone Acetonide / therapeutic use
  • Fluocinonide / therapeutic use
  • Humans
  • Hydrocortisone / therapeutic use
  • Male
  • Middle Aged
  • Mucous Membrane
  • Prednisone / therapeutic use
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Triamcinolone / therapeutic use
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Fluocinolone Acetonide
  • Triamcinolone
  • Fluocinonide
  • Clindamycin
  • fluocinolone
  • Prednisone
  • Hydrocortisone